Regeneron Pharmaceuticals, Inc.

Parsa Akbari

Aris I Baras

Luca Andrea Lotta

Manuel Allen Revez Ferreira

Olukayode Sosina

Niek Verweij

Adam Locke

The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.

Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.

Growing community of inventors

Tarrytown, NY, United States of America

Parsa Akbari